Company Overview

Concord Drugs Limited, a pharmaceutical company, reported exceptional financial performance for FY26 and announced its 31st Annual General Meeting scheduled for 30 September 2026.

Financial Performance Highlights

Standalone Results (₹ in Lakhs):

  • Revenue from Operations: ₹7,584.86 (up 105.37% from ₹3,693.21 in FY25)
  • Profit Before Tax: ₹144.86 (up 125.88% from ₹64.13)
  • Profit After Tax: ₹103.74 (up 250.83% from ₹29.57)
  • EPS: ₹0.93 (up 210% from ₹0.30)

Consolidated Results (₹ in Lakhs):

  • Revenue from Operations: ₹7,873.68 (up 74.03% from ₹4,524.46)
  • Profit After Tax: ₹105.50 (up 213.80% from ₹33.62)
  • EPS: ₹0.95 (up 179.41% from ₹0.34)

The company achieved significant growth across all key financial metrics, with revenue nearly doubling and profits more than tripling year-over-year.

AGM Details and Resolutions

The 31st AGM will be held on 30 September 2026 via video conference. Key agenda items include:

  • Adoption of FY26 financial statements
  • Reappointment of Mr. S. Nagi Reddy as Director
  • Reappointment of M/s. Pundarikashyam and Associates as Statutory Auditors for five years
  • Approval of related party transactions up to ₹15 crore each with associate companies
  • Reappointment of independent directors Mr. S. Nagavenkata Hareesh Kumar Solleti and Ms. Sumeela Kasu

Capital Structure Changes

  • Authorized Share Capital increased from ₹11.00 Crores to ₹15.50 Crores
  • Completed preferential issue of 31,75,000 Equity Shares at ₹36.30 per share and 20,25,000 Convertible Warrants
  • Paid-up Equity Share Capital increased from ₹10.00 Crores to ₹13.175 Crores
  • Securities Premium Account balance increased to ₹1,693.96 lakh

Subsidiary and Corporate Structure

The company holds 100% ownership in Proton Remedies Private Limited. Significant related party transactions were conducted with associate companies including Cortex Laboratories, Seelam Laboratories, and Continental Pellets Pharma.

Regulatory and Compliance Matters

  • Ongoing income tax dispute of ₹258.82 lakh for Assessment Year 2011-12 under section 143(3)
  • Complied with SEBI Listing Regulations
  • Secretarial audit revealed minor observations regarding delayed filings
  • No dividend recommended for FY26 to utilize funds for improving shareholder value

Key Dates and Shareholding

  • Record Date: 23 September 2026
  • Remote E-voting: 27-29 September 2026
  • Promoter holding: 54.39% as of 31 March 2026
  • Dematerialized holdings: 94.29%

The company demonstrates strong operational performance with substantial growth in revenue and profitability, while maintaining compliance with regulatory requirements and planning for future expansion through capital restructuring.